Netramark signs contract for client's depression trial

Executive Summary

• Netramark Holdings Inc. has signed a contract with a leading global biopharmaceutical company to analyze Phase 2 clinical trial data for depression.
• The engagement will utilize Netramark's proprietary NetraAI platform to identify patient subpopulations, evaluate treatment response patterns, and generate insights to optimize future study design.
• This collaboration expands Netramark's portfolio of AI-driven projects in CNS disorders and validates the platform's ability to process complex, small clinical datasets to enrich drug development trials.

Key Details

• Contract Counterparty: Leading global biopharmaceutical company developing innovative treatments for psychiatric and neurological disorders.
• Project Scope: Analysis of Phase 2 clinical trial data for depression.
• Technology Deployed: Netramark's proprietary NetraAI platform, leveraging a dynamical systems framework designed to overcome traditional machine learning limitations.
• Analytical Objectives: Uncover potential patient phenotypes, evaluate treatment-related response patterns, generate hypothesis-driven insights, and stratify high-effect-size patient subpopulations.
• Strategic Impact: Extends Netramark's growing portfolio of AI-driven projects in depression and CNS disorders, demonstrating capacity to deliver actionable precision trial insights.
• Platform Capabilities: Utilizes a novel topology-based algorithm to parse patient datasets into strongly related subsets, enabling accurate disease segmentation and patient classification for drug sensitivity/efficacy even with smaller data sets.

Notable Quotes

• George Achilleos, CEO: "We believe this engagement reflects the demand from pharmaceutical companies to better understand the patient heterogeneity in clinical trials."
• George Achilleos, CEO: "By analyzing this phase 2 data set, we aim to identify the patient subpopulations most likely to benefit from treatment and provide insights that may inform our sponsor's future study design with greater precision and confidence."